Page 1

HAEMONETICSⓇ Investor Contact Media Contact Olga Guyette , Director - Investor Relations Josh Gitelson , Director - Communications ( 781 ) 356-9763 ( 781 ) 356-9776 olga.guyette@haemonetics.com Haemonetics Reports First Quarter Fiscal 2022 Results ; Increases Guidance for Vascular Closure Revenue and Affirms All Other Fiscal 2022 Guidance ; Expands Operational Excellence Program Boston , MA , August 11 , 2021 - Haemonetics Corporation ( NYSE : HAE ) reported financial results for its first quarter of fiscal 2022 , which ended July 3 , 2021 : ■ Revenue , increase ■ Revenue increase ( organic ) ¹ ▪ Loss per share ■ Adjusted earnings per diluted share ■ Cash flow from operating activities GAAP RESULTS ■ Free cash flow before restructuring & restructuring related costs ¹ Excludes the impact of currency fluctuation , strategic exits of product lines , acquisitions and divestitures . josh.gitelson@haemonetics.com Chris Simon , Haemonetics ' CEO , stated : " Our first quarter performance is a positive start to the year , supported by recovery across all of our businesses , especially Hospital , and the initial Plasma Persona® rollouts . We remain confident in the strong end - market demand for our products and continue to anticipate full recovery from the pandemic by the end of this fiscal year . Our revised Operational Excellence Program will drive quality , service and greater productivity , while helping us to offset impacts of the anticipated customer loss , the effects of the COVID - 19 pandemic and rising inflationary pressures . " ( $ millions ) First quarter fiscal 2022 revenue was $ 228.5 million , up 16.8 % compared with fiscal 2021 . Business unit revenue and growth rates compared with the prior year were as follows : Plasma Hospital Blood Center Net business unit revenue Service Total net revenue 1st Quarter 2022 $ 229 million , 17 % 6 % ( $ 0.09 ) $ 0.50 ( $ 2 ) million $ 2 million 1st Quarter 2022 Reported $ 71.8 $ 78.5 $ 72.9 $ 223.3 $ 5.2 $ 228.5 5.3 % 75.1 % ( 6.2 % ) 17.0 % 10.7 % 16.8 % 1